Articles by Sanjay Garg, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Sanjay Garg, PhD

Sanjay Garg, PhD

Associate Professor

Sanjay Garg, PhD, is an associate professor at the School of Pharmacy, University of Auckland, Auckland, New Zealand, and a member of the Pharmaceutical Technology Editorial Advisory Board.

Articles
Biopharmaceutical Form and Function
June 2, 2010

A timely new book explains techniques for conformational analysis.

Quality in, Quality Out
June 2, 2009

A book guides readers through the regulatory requirements for computerized quality systems.

A Peak in Mass-Spectrometry Literature
December 2, 2008

A book about pharmaceutical analysis engages the reader with history and unexpected asides.

Charting a Path to Purity
October 2, 2007

Regulators and industry professionals provide a guide for identifying and measuring impurities.

An Update on Osmotic Drug Delivery
August 2, 2003

The authors review patent literature that describes new developments in osmotic drug delivery such as pulsatile, delayed, and volume amplifier delivery devices.

Current Status of Drug Delivery Technologies and Future Directions
February 2, 2001

Evolution of an existing drug molecule from a conventional form to a novel delivery system can significantly improve its performance in terms of patient compliance, safety, and efficacy. These days,drug delivery companies are engaged in the development of multiple platform technologies to get competitive advantage, extend patent life, and increase market share of their products.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here